Form 6-K BioLineRx Ltd. For: Nov 16
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Maxim Affirms BiolineRx (BLRX) at 'Buy'; BL-8040 Should be Focus for Immune Oncology Segment
November 16, 2015 2:51 PM ESTMaxim affirms BiolineRx (Nasdaq: BLRX) with a Buy rating and $4 price target following Q3 results reported Monday morning.
The firm summarized:
Pipeline Update: BL-8040 phase II data in relapsed/refractory AML (Acute Myeloid Leukemia) showing a 38% composite response rate will be presented at ASH (December 5-8, 2015), and... MoreBioLineRx (BLRX) Tops Q3 EPS by 6c
November 16, 2015 8:34 AM ESTBioLineRx (NASDAQ: BLRX) reported Q3 EPS of ($0.02), $0.06 better than the analyst estimate of ($0.08).
For earnings history and earnings-related data on BioLineRx (BLRX) click here.
... More